ADDvise announces preliminary results for Q2 2023 that are stronger than expected

13-07-2023   Regulatory press release

The preliminary results for ADDvise Group for the second quarter of 2023 significantly deviate from what ADDvise assesses as the market expectations.

SEK million

Q2 2023

Q2 2022

 LTM June 2023

Net sales




Gross profit




Gross margin %








EBITDA margin %








EBITA margin %





The financial targets for the full year 2023, as previously communicated, are a pro forma EBITDA result of SEK 330 million and a pro forma net revenue of SEK 1.6 billion. Pro forma is calculated assuming that all acquisitions made during the current fiscal year are consolidated for the entire fiscal year. No new acquisitions have been consolidated in the second quarter of 2023.


The finance net in the second quarter will be negatively affected by one-time costs related to the refinancing of the previous bond in the amount of 37.1 MSEK.

The above-presented financial information is preliminary and will not be commented on by ADDvise Group until the report for the second quarter has been released.


ADDvise Group's report for the second quarter of 2023 will be published on July 20, 2023, at 07:45 am CEST.


ADDvise Group will hold an investor presentation at 1:00 pm CEST for investors and analysts. Please use the link below to participate:


Important information
This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on July 13, 2023 at 08:00 am CEST.

For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at


Latest press releases

ADDvise Group’s CEO divests shares - remains a committed and long-term shareholder


Rikard Akhtarzand, CEO of ADDvise Group AB (publ) (“ADDvise” or the “Company”), has informed the Company that he has sold 2,500,000 Class B shares in ADDvise, representing approximately 1.3% of total outstanding shares and 18.1% of his total shareholding in the Company, and that he has entered a 180-day lock-up agreement for his remaining shares.…

ADDvise acquires Diabetic Supplies Inc.


ADDvise Group has today entered into a share purchase agreement with the owners of Diabetic Supplies Inc. (“Diabetic Supplies”) regarding the acquisition of all shares of Diabetic Supplies in accordance with the letter of intent previously communicated. Closing of the acquisition is expected to take place at the beginning of September 2023. Diabetic Supplies’ revenue…

ADDvise receives order worth USD 4 million


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Tecnimont. The order involves the design endorsement, supply, and installation of multiple cleanroom facilities as part of a larger industrial project. The order is worth approximately USD 4 million. Tecnimont, a subsidiary of Maire, is a leading integrated engineering and construction services and…

ADDvise Group recruits Oliver Humlen as new CFO


ADDvise recruits Oliver Humlen as new CFO and member of the executive management team. Oliver has more than a decade of experience from investment banking. He joins ADDvise from Pareto Securities where he has been working within Debt Capital Markets for the past nine years, of which six as Partner. Prior to that, he worked…